ClinicalTrials.gg
CompletedNCT06577155Updated May 12, 2026

Spinal Nalbuphine for Analgesia in Total Hip Arthroplasty

A Phase 2 interventional study of Levobupivacaine and Levobupivacaine plus nalbuphine in Total Hip Arthroplasty and Analgesia, sponsored by Asklepieion Voulas General Hospital. Completed at 1 site in Greece. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Asklepieion Voulas General Hospital · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

60 patients ASA I-III, undergoing total hip arthroplasty were randomly assigned, into one of two groups, namely group E (n=30), where levobupivacaine will be administeral intrathecally ; and group N (n=30), where levobupivacaine plus nalbuphine will be administeral intrathecally. All patients will receive a standardized multimodal analgesic regimen, including a PENG block and PCA morphine. Morphine consumption during the first 24 hours postoperatively will be measured and additionally the investigators will record: Time of morphine first dose administration, NRS scores in static and dynamic conditions in 4 hours, 6 hours, 12 hours, 18 hours, 24 hours, 36 hours and 48 hours postoperatively, complications, patient satisfaction and duration of hospitalization.

02

Conditions studied

  • Total Hip Arthroplasty
  • Analgesia
03

In context

Lead sponsor

Asklepieion Voulas General Hospital is the lead sponsor of 13 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physical status according to (ASA) I-III
  • Patients scheduled for total hip arthroplasty

Exclusion criteria

Exclusion Criteria:

  • above 40
  • Serious psychiatric, mental and cognitive disorders
  • for central and/or peripheral nervous blockade
  • History of allergic or other adverse reactions on the agents used in the study
  • Chronic opioid
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    E

    Spinal levobupivacaine

    Drug: Levobupivacaine

  • Active comparator
    N

    Spinal levobupivacaine plus nalbuphine

    Drug: Levobupivacaine plus nalbuphine

Interventions

06

What researchers measure

Primary outcomes

  1. Morphine consumption

    Time frame: 24 hours

  2. NRS scores

    Time frame: 48 hours

Secondary outcomes

  1. sensory block level

    Time frame: 1 hour

  2. motor block level

    Time frame: 1 hour

  3. sensory block onset

    Time frame: 1 hour

  4. motor block onset

    Time frame: 1 hour

  5. sensory block duration

    Time frame: 4 hours

  6. motor block duration

    Time frame: 4 hours

  7. Complications

    Time frame: 24 hours

07

Study locations

1 site
  • Asklepieion Hospital of Voula
    Athens, Ελλάδα (+30) 16675, Greece
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Jan 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2024
First posted
Aug 29, 2024
StartActual
Aug 29, 2024
Primary completionActual
Jan 21, 2025
CompletionActual
Jan 21, 2025
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06577155
Lead sponsor
Asklepieion Voulas General Hospital
Collaborators
Anastasios Mpontozis
Responsible party
Alexandros Makris (Consultant Anaesthesiologist, Asklepieion Voulas General Hospital) — Principal investigator
First posted
Aug 29, 2024
Start date
Aug 29, 2024
Primary completion
Jan 21, 2025
Completion
Jan 21, 2025
Last update
May 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levobupivacaine · Nalbuphine

Start the discussion